Allergan Drug Patent Portfolio
Allergan owns 11 orange book drugs protected by 38 US patents with Alocril having the least patent protection, holding only 1 patent. And Oxytrol with maximum patent protection, holding 8 patents. Given below is the list of Allergan's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US7741358 | Crystal form of asenapine maleate | 06 Oct, 2026 | Active |
| US8022228 | Crystal form of asenapine maleate | 06 Oct, 2026 | Active |
| US7741358 | Crystal form of asenapine maleate | 06 Apr, 2026 | Active |
| US8022228 | Crystal form of asenapine maleate | 06 Apr, 2026 | Active |
| US7410978 | Once daily dosage forms of trospium | 01 Feb, 2025 | Active |
| US7759359 | Method of treating bladder dysfunction with once-a-day trospium salt formulation | 04 Nov, 2024 | Expired |
| US7763635 | Once daily dosage forms of trospium | 04 Nov, 2024 | Expired |
| US7781448 | Once daily dosage forms of trospium | 04 Nov, 2024 | Expired |
| US7781449 | Trospium chloride treatment method | 04 Nov, 2024 | Expired |
| US7198801 | Formulations for transdermal or transmucosal application | 25 Jun, 2022 | Expired |
| US6545040 | Method of lowering the blood pressure | 17 Dec, 2021 | Expired |
| US5763476 | Sublingual or buccal pharmaceutical composition | 09 Dec, 2020 | Expired |
| US5763476 | Sublingual or buccal pharmaceutical composition | 09 Jun, 2020 | Expired |
| US7029694 | Compositions and methods for transdermal oxybutynin therapy | 26 Apr, 2020 | Expired |
| US7179483 | Compositions and methods for transdermal oxybutynin therapy | 26 Apr, 2020 | Expired |
| US8241662 | Unoccluded topical oxybutynin gel composition and methods for transdermal oxybutynin therapy | 26 Apr, 2020 | Expired |
| US6743441 | Compositions and methods for minimizing adverse drug experiences associated with oxybutynin therapy | 26 Apr, 2020 | Expired |
| US7081249 | Compositions and methods for minimizing adverse drug experiences associated with oxybutynin therapy | 26 Apr, 2020 | Expired |
| US7081250 | Compositions and methods for minimizing adverse drug experiences associated with oxybutynin therapy | 26 Apr, 2020 | Expired |
| US7081251 | Compositions and methods for minimizing adverse drug experiences associated with oxybutynin therapy | 26 Apr, 2020 | Expired |
| US7081252 | Compositions and methods for minimizing adverse drug experiences associated with oxybutynin therapy | 26 Apr, 2020 | Expired |
| US6333045 | Aqueous liquid pharmaceutical composition comprised of gatifloxacin | 20 Feb, 2020 | Expired |
| US6333045 | Aqueous liquid pharmaceutical composition comprised of gatifloxacin | 20 Aug, 2019 | Expired |
| US5387603 | 1,5,7-trisubstituted indoline compounds and salts thereof | 01 Dec, 2018 | Expired |
| US5880283 | 8-alkoxyquinolonecarboxylic acid hydrate with excellent stability and process for producing the same | 05 Jun, 2016 | Expired |
| US5880283 | 8-alkoxyquinolonecarboxylic acid hydrate with excellent stability and process for producing the same | 05 Dec, 2015 | Expired |
| US5061703 | Adamantane derivatives in the prevention and treatment of cerebral ischemia | 11 Oct, 2015 | Expired |
| US5759580 | Compositions containing micronized nebivolol | 02 Jun, 2015 | Expired |
| US5601839 | Triacetin as a penetration enhancer for transdermal delivery of a basic drug | 26 Apr, 2015 | Expired |
| US5834010 | Triacetin as a penetration enhancer for transdermal delivery of a basic drug | 26 Apr, 2015 | Expired |
| US5061703 | Adamantane derivatives in the prevention and treatment of cerebral ischemia | 11 Apr, 2015 | Expired |
| US5914334 | Stable gel formulation for topical treatment of skin conditions | 07 Jun, 2014 | Expired |
| US6258830 | Stable gel formulation for topical treatment of skin conditions | 07 Jun, 2014 | Expired |
| US5543150 | Method of progesterone delivery and affect thereof | 15 Sep, 2013 | Expired |
| US5403847 | Use of α1C specific compounds to treat benign prostatic hyperlasia | 13 Nov, 2012 | Expired |
| US5780485 | Use of α1c specific compounds to treat benign prostatic hyperplasia | 13 Nov, 2012 | Expired |
| US6015819 | Use of alpha-1C specific compounds to treat benign prostatic hyperplasia | 13 Nov, 2012 | Expired |
| USRE38628 | Pharmaceutical compositions | 22 Aug, 2012 | Expired |
Latest Legal Activities on Allergan's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Allergan.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
|
Maintenance Fee Reminder Mailed
Critical
| 01 Apr, 2024 | US8241662 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 08 Feb, 2023 | US8022228 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 11 Nov, 2021 | US7741358 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 14 Feb, 2020 | US8241662 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 20 Mar, 2019 | US8022228 |
|
Expire Patent
Critical
| 01 Oct, 2018 | US7781449 (Litigated) |
|
Expire Patent
Critical
| 01 Oct, 2018 | US7781448 (Litigated) |
| Payment of Maintenance Fee, 12th Year, Large Entity | 20 Sep, 2018 | US7198801 |
|
Expire Patent
Critical
| 03 Sep, 2018 | US7763635 (Litigated) |
|
Expire Patent
Critical
| 27 Aug, 2018 | US7759359 (Litigated) |
| Payment of Maintenance Fee, 12th Year, Large Entity | 22 Aug, 2018 | US7179483 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 22 Aug, 2018 | US7179483 |
|
Maintenance Fee Reminder Mailed
Critical
| 09 Apr, 2018 | US7781449 (Litigated) |
|
Maintenance Fee Reminder Mailed
Critical
| 09 Apr, 2018 | US7781448 (Litigated) |
|
Maintenance Fee Reminder Mailed
Critical
| 12 Mar, 2018 | US7763635 (Litigated) |
Allergan's Drug Patent Litigations
Allergan's drugs have been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Jun 12, 1996, against patent number US6545040. The petitioner , challenged the validity of this patent, with XHONNEUX et al as the respondent. Click below to track the latest information on how companies are challenging Allergan's patents.
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
 | ||||
| US6545040 | December, 2015 |
Terminated-Denied
(01 Jul, 2016)
| Forest Laboratories Holdings Limited | Lower Drug Prices For Consumers, LLC |
| US6545040 | June, 1996 |
Decision
(14 Mar, 2000)
| XHONNEUX et al | |
Allergan's Family Patents
Allergan Drug List
Given below is the complete list of Allergan's drugs and the patents protecting them.
1. Alocril
Alocril is protected by 1 patent, which has expired already. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| USRE38628 | Pharmaceutical compositions |
22 Aug, 2012
(12 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Alocril's drug page
2. Bystolic
Bystolic is protected by 2 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US6545040 | Method of lowering the blood pressure |
17 Dec, 2021
(2 years ago)
| Expired |
| US5759580 | Compositions containing micronized nebivolol |
02 Jun, 2015
(9 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Bystolic's drug page
3. Crinone
Crinone is protected by 1 patent, which has expired already. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US5543150 | Method of progesterone delivery and affect thereof |
15 Sep, 2013
(11 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Crinone's drug page
4. Gelnique 3%
Gelnique 3% is protected by 4 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US7198801 | Formulations for transdermal or transmucosal application |
25 Jun, 2022
(2 years ago)
| Expired |
| US7029694 | Compositions and methods for transdermal oxybutynin therapy |
26 Apr, 2020
(4 years ago)
| Expired |
| US7179483 | Compositions and methods for transdermal oxybutynin therapy |
26 Apr, 2020
(4 years ago)
| Expired |
| US8241662 | Unoccluded topical oxybutynin gel composition and methods for transdermal oxybutynin therapy |
26 Apr, 2020
(4 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Gelnique 3%'s drug page
5. Namenda
Namenda is protected by 2 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US5061703
(Pediatric)
| Adamantane derivatives in the prevention and treatment of cerebral ischemia |
11 Oct, 2015
(9 years ago)
| Expired |
| US5061703 | Adamantane derivatives in the prevention and treatment of cerebral ischemia |
11 Apr, 2015
(9 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Namenda's drug page
Explore Our Curated Drug Screens
6. Oxytrol
Oxytrol is protected by 8 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US6743441 | Compositions and methods for minimizing adverse drug experiences associated with oxybutynin therapy |
26 Apr, 2020
(4 years ago)
| Expired |
| US7081249 | Compositions and methods for minimizing adverse drug experiences associated with oxybutynin therapy |
26 Apr, 2020
(4 years ago)
| Expired |
| US7081250 | Compositions and methods for minimizing adverse drug experiences associated with oxybutynin therapy |
26 Apr, 2020
(4 years ago)
| Expired |
| US7081251 | Compositions and methods for minimizing adverse drug experiences associated with oxybutynin therapy |
26 Apr, 2020
(4 years ago)
| Expired |
| US7081252 | Compositions and methods for minimizing adverse drug experiences associated with oxybutynin therapy |
26 Apr, 2020
(4 years ago)
| Expired |
| US7179483 | Compositions and methods for transdermal oxybutynin therapy |
26 Apr, 2020
(4 years ago)
| Expired |
| US5601839 | Triacetin as a penetration enhancer for transdermal delivery of a basic drug |
26 Apr, 2015
(9 years ago)
| Expired |
| US5834010 | Triacetin as a penetration enhancer for transdermal delivery of a basic drug |
26 Apr, 2015
(9 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Oxytrol's drug page
7. Rapaflo
Rapaflo is protected by 4 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US5387603 | 1,5,7-trisubstituted indoline compounds and salts thereof |
01 Dec, 2018
(5 years ago)
| Expired |
| US5403847 | Use of α1C specific compounds to treat benign prostatic hyperlasia |
13 Nov, 2012
(12 years ago)
| Expired |
| US5780485 | Use of α1c specific compounds to treat benign prostatic hyperplasia |
13 Nov, 2012
(12 years ago)
| Expired |
| US6015819 | Use of alpha-1C specific compounds to treat benign prostatic hyperplasia |
13 Nov, 2012
(12 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Rapaflo's drug page
8. Sanctura Xr
Sanctura Xr is protected by 5 patents, out of which 4 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US7410978 | Once daily dosage forms of trospium |
01 Feb, 2025
(2 months from now)
| Active |
| US7759359 | Method of treating bladder dysfunction with once-a-day trospium salt formulation |
04 Nov, 2024
(11 days ago)
| Expired |
| US7763635 | Once daily dosage forms of trospium |
04 Nov, 2024
(11 days ago)
| Expired |
| US7781448 | Once daily dosage forms of trospium |
04 Nov, 2024
(11 days ago)
| Expired |
| US7781449 | Trospium chloride treatment method |
04 Nov, 2024
(11 days ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Sanctura Xr's drug page
9. Saphris
Saphris is protected by 6 patents, out of which 2 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US7741358
(Pediatric)
| Crystal form of asenapine maleate |
06 Oct, 2026
(1 year, 10 months from now)
| Active |
| US8022228
(Pediatric)
| Crystal form of asenapine maleate |
06 Oct, 2026
(1 year, 10 months from now)
| Active |
| US7741358 | Crystal form of asenapine maleate |
06 Apr, 2026
(1 year, 4 months from now)
| Active |
| US8022228 | Crystal form of asenapine maleate |
06 Apr, 2026
(1 year, 4 months from now)
| Active |
| US5763476
(Pediatric)
| Sublingual or buccal pharmaceutical composition |
09 Dec, 2020
(3 years ago)
| Expired |
| US5763476 | Sublingual or buccal pharmaceutical composition |
09 Jun, 2020
(4 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Saphris's drug page
10. Tazorac
Tazorac is protected by 2 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US5914334 | Stable gel formulation for topical treatment of skin conditions |
07 Jun, 2014
(10 years ago)
| Expired |
| US6258830 | Stable gel formulation for topical treatment of skin conditions |
07 Jun, 2014
(10 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Tazorac's drug page
11. Zymar
Zymar is protected by 4 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US6333045
(Pediatric)
| Aqueous liquid pharmaceutical composition comprised of gatifloxacin |
20 Feb, 2020
(4 years ago)
| Expired |
| US6333045 | Aqueous liquid pharmaceutical composition comprised of gatifloxacin |
20 Aug, 2019
(5 years ago)
| Expired |
| US5880283
(Pediatric)
| 8-alkoxyquinolonecarboxylic acid hydrate with excellent stability and process for producing the same |
05 Jun, 2016
(8 years ago)
| Expired |
| US5880283 | 8-alkoxyquinolonecarboxylic acid hydrate with excellent stability and process for producing the same |
05 Dec, 2015
(8 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Zymar's drug page